The results of previous IPMN HGD studies are consistent with the present findings that showed that apoA2-ATQ/AT detected patients with early-stage pancreatic cancer, such as stage I, with greater sensitivity than CA19-9. Here, APOA2 is linked to pancreatic intraductal papillary-mucinous neoplasm.